Search review questions

Change in distance BCVA in the amblyopic eye 12 months after cessation of treatment · 5‐ to 8‐year‐old children with amblyopia

Adherence to intervention Proportion of adherence to prescribed intervention across predefined categories · 5‐ to 8‐year‐old children with amblyopia

Proportion of participants experiencing an adverse event of permanent diplopia (double vision) Reports of diplopia across all measured time points · 5‐ to 8‐year‐old children with amblyopia

Change in the interocular difference in contrast sensitivity Any validated test, from baseline to 16 (± 2) weeks · 5‐ to 8‐year‐old children with amblyopia

Measurable change in stereopsis after 8 (± 2) weeks and 16 (± 2) weeks of intervention 'Real change' in stereopsis is defined as a change in stereoacuity of two or more octaves. · 5‐ to 8‐year‐old children with amblyopia

Outcomes* · eyes with acute endophthalmitis following an intraocular procedure (e.g. surgery, intravitreous injection)

Complete resolution of endophthalmitis at 3 months' · eyes with acute endophthalmitis following an intraocular procedure (e.g. surgery, intravitreous injection)

Visual acuity 6/6 to 6/18 at 3 months' · eyes with acute endophthalmitis following an intraocular procedure (e.g. surgery, intravitreous injection)

Visual acuity 6/6 to 6/18, or LogMAR 0.3 or better at 12 months' · eyes with acute endophthalmitis following an intraocular procedure (e.g. surgery, intravitreous injection)

Improvement in visual acuity at 3 months' · eyes with acute endophthalmitis following an intraocular procedure (e.g. surgery, intravitreous injection)

Intraocular pressure at 12 months' · eyes with acute endophthalmitis following an intraocular procedure (e.g. surgery, intravitreous injection)

Adverse events at 3 to 12 months' · eyes with acute endophthalmitis following an intraocular procedure (e.g. surgery, intravitreous injection)

Costs associated with the interventions at 3 months' · eyes with acute endophthalmitis following an intraocular procedure (e.g. surgery, intravitreous injection)

Endophthalmitis · people with bilateral age‐related cataracts (RCTs)

Complications · people with bilateral age‐related cataracts (NRSs)

Total costs per participant · people with bilateral age‐related cataracts (NRSs)

Total costs per QALY · people with bilateral age‐related cataracts (NRSs)

BCDVA · people with bilateral age‐related cataracts (NRSs)

PROM · people with bilateral age‐related cataracts (NRSs)

Refraction NOT within 1.0 dioptres of target · people with bilateral age‐related cataracts (RCTs)

Complications · people with bilateral age‐related cataracts (RCTs)

Total costs per participant · people with bilateral age‐related cataracts (RCTs)

Total costs per QALY · people with bilateral age‐related cataracts (RCTs)

BCDVA · people with bilateral age‐related cataracts (RCTs)

PROMs · people with bilateral age‐related cataracts (RCTs)

Endophthalmitis · people with bilateral age‐related cataracts (NRSs)

Refraction NOT within 1.0 dioptres of target · people with bilateral age‐related cataracts (NRSs)

Proportion of participants with sustained remission (as defined by study investigators) at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Proportion of participants with sustained remission (as defined by study investigators) at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Proportion of participants with relapse‐free survival at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Proportion of all‐cause mortality at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Mean time to first relapse after induction of remission (weeks) at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Proportion of participants who did not need escape therapy (as defined by study investigators) · adults aged over 50 years with giant cell arteritis

Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey physical component score (SF‐36 PCS) · adults aged over 50 years with giant cell arteritis

Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) · adults aged over 50 years with giant cell arteritis

Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Proportion of participants with relapse‐free survival at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Proportion of participants with sustained remission (as defined by study investigators) at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Proportion of participants with relapse‐free survival at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Proportion of all‐cause mortality at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Mean time to first relapse after induction of remission (weeks) at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Proportion of participants who did not need escape therapy (as defined by study investigators) · adults aged over 50 years with giant cell arteritis

Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey physical component score (SF‐36 PCS) · adults aged over 50 years with giant cell arteritis

Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) · adults aged over 50 years with giant cell arteritis

Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Proportion of all‐cause mortality at ≥ 12 months · adults aged over 50 years with giant cell arteritis